lorlatinib
Selected indexed studies
- First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer. (N Engl J Med, 2020) [PMID:33207094]
- Lorlatinib Versus Crizotinib in Patients With Advanced ALK-Positive Non-Small Cell Lung Cancer: 5-Year Outcomes From the Phase III CROWN Study. (J Clin Oncol, 2024) [PMID:38819031]
- A pragmatic guide for management of adverse events associated with lorlatinib. (Lung Cancer, 2024) [PMID:38554546]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer. (2020) pubmed
- Lorlatinib Versus Crizotinib in Patients With Advanced ALK-Positive Non-Small Cell Lung Cancer: 5-Year Outcomes From the Phase III CROWN Study. (2024) pubmed
- A pragmatic guide for management of adverse events associated with lorlatinib. (2024) pubmed
- Lorlatinib. (2012) pubmed
- Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: updated analysis of data from the phase 3, randomised, open-label CROWN study. (2023) pubmed
- Lorlatinib: First Global Approval. (2019) pubmed
- Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study. (2018) pubmed
- Lorlatinib as a treatment for ALK-positive lung cancer. (2022) pubmed
- Clinical Management of Adverse Events Associated with Lorlatinib. (2019) pubmed
- Lorlatinib with or without chemotherapy in ALK-driven refractory/relapsed neuroblastoma: phase 1 trial results. (2023) pubmed